Fred E. Bertrand - Publications

Affiliations: 
Microbiology and Immunology East Carolina University, Greenville, NC, United States 
Area:
Immunology, Oncology

30 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2015 Vinson KE, George DC, Fender AW, Bertrand FE, Sigounas G. The Notch pathway in colorectal cancer. International Journal of Cancer. Journal International Du Cancer. PMID 26264352 DOI: 10.1002/ijc.29800  0.32
2015 Fender AW, Nutter JM, Fitzgerald TL, Bertrand FE, Sigounas G. Notch-1 promotes stemness and epithelial to mesenchymal transition in colorectal cancer. Journal of Cellular Biochemistry. 116: 2517-27. PMID 25914224 DOI: 10.1002/jcb.25196  0.32
2014 McCubrey JA, Steelman LS, Bertrand FE, Davis NM, Sokolosky M, Abrams SL, Montalto G, D'Assoro AB, Libra M, Nicoletti F, Maestro R, Basecke J, Rakus D, Gizak A, Demidenko ZN, et al. GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget. 5: 2881-911. PMID 24931005 DOI: 10.18632/oncotarget.2037  0.32
2014 McCubrey JA, Steelman LS, Bertrand FE, Davis NM, Abrams SL, Montalto G, D'Assoro AB, Libra M, Nicoletti F, Maestro R, Basecke J, Cocco L, Cervello M, Martelli AM. Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention. Leukemia. 28: 15-33. PMID 23778311 DOI: 10.1038/leu.2013.184  0.32
2011 Dong K, Feng Y, Jacobs KM, Lu JQ, Brock RS, Yang LV, Bertrand FE, Farwell MA, Hu XH. Label-free classification of cultured cells through diffraction imaging. Biomedical Optics Express. 2: 1717-26. PMID 21698031 DOI: 10.1364/BOE.2.001717  0.32
2009 Whelan JT, Kellogg A, Shewchuk BM, Hewan-Lowe K, Bertrand FE. Notch-1 signaling is lost in prostate adenocarcinoma and promotes PTEN gene expression. Journal of Cellular Biochemistry. 107: 992-1001. PMID 19479935 DOI: 10.1002/Jcb.22199  0.32
2008 Whelan JT, Ludwig DL, Bertrand FE. HoxA9 induces insulin-like growth factor-1 receptor expression in B-lineage acute lymphoblastic leukemia. Leukemia. 22: 1161-9. PMID 18337761 DOI: 10.1038/leu.2008.57  0.32
2007 Whelan JT, Forbes SL, Bertrand FE. CBF-1 (RBP-J kappa) binds to the PTEN promoter and regulates PTEN gene expression. Cell Cycle (Georgetown, Tex.). 6: 80-4. PMID 17245125  0.32
2007 Ojeda JF, Xie C, Li YQ, Bertrand FE, Wiley J, McConnell TJ. Chromosomal analysis and identification based on optical tweezers and Raman spectroscopy: Reply Optics Express. 15: 6000-6002. DOI: 10.1364/OE.15.006000  0.32
2007 McCubrey JA, Bertrand FE, Steelman LS, Chang F, Terrian DM, Franklin RA. Critical roles of the Raf/MEK/ERK pathway in apoptosis and drug resistance Apoptosis, Cell Signaling, and Human Diseases. 2: 101-134. DOI: 10.1007/978-1-59745-199-4_5  0.32
2006 Basecke J, Whelan JT, Griesinger F, Bertrand FE. The MLL partial tandem duplication in acute myeloid leukaemia. British Journal of Haematology. 135: 438-49. PMID 16965385 DOI: 10.1111/j.1365-2141.2006.06301.x  0.32
2006 McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance Advances in Enzyme Regulation. 46: 249-279. PMID 16854453 DOI: 10.1016/J.Advenzreg.2006.01.004  0.32
2006 Bertrand FE, Steelman LS, Chappell WH, Abrams SL, Shelton JG, White ER, Ludwig DL, McCubrey JA. Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells. Leukemia. 20: 1254-60. PMID 16642049 DOI: 10.1038/sj.leu.2404217  0.32
2005 Shelton JG, Steelman LS, Abrams SL, Bertrand FE, Franklin RA, McMahon M, McCubrey JA. The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: what's genetics got to do with it? Expert Opinion On Therapeutic Targets. 9: 1009-30. PMID 16185155 DOI: 10.1517/14728222.9.5.1009  0.32
2005 Chappell WH, Green TD, Spengeman JD, McCubrey JA, Akula SM, Bertrand FE. Increased protein expression of the PTEN tumor suppressor in the presence of constitutively active Notch-1. Cell Cycle (Georgetown, Tex.). 4: 1389-95. PMID 16096376  0.32
2005 McCubrey JA, Bertrand FE. Upping the bid on engineered inducible cell death. Cancer Biology & Therapy. 4: 537. PMID 15970693  0.32
2005 Bertrand FE, McCubrey JA. Acquired immunodeficiency syndrome associated lymphoma. Frontiers in Bioscience : a Journal and Virtual Library. 10: 2972-7. PMID 15970551  0.32
2005 Shelton JG, Steelman LS, Abrams SL, White ER, Akula SM, Franklin RA, Bertrand FE, McMahon M, McCubrey JA. Conditional EGFR promotes cell cycle progression and prevention of apoptosis in the absence of autocrine cytokines. Cell Cycle (Georgetown, Tex.). 4: 822-30. PMID 15917660 DOI: 10.4161/Cc.4.6.1724  0.32
2005 Shelton JG, Steelman LS, Abrams SL, White ER, Akula SM, Bertrand FE, Franklin RA, McCubrey JA. Effects of endogenous epidermal growth factor receptor signaling on DNA synthesis and ERK activation in a cytokine-dependent hematopoietic cell line. Cell Cycle (Georgetown, Tex.). 4: 818-21. PMID 15908804  0.32
2005 Spengeman JD, Green TD, McCubrey JA, Bertrand FE. Activated EGFR promotes the survival of B-lineage acute leukemia in the absence of stromal cells. Cell Cycle (Georgetown, Tex.). 4: 483-7. PMID 15701973  0.32
2005 Bertrand FE, Spengemen JD, Shelton JG, McCubrey JA. Inhibition of PI3K, mTOR and MEK signaling pathways promotes rapid apoptosis in B-lineage ALL in the presence of stromal cell support. Leukemia. 19: 98-102. PMID 15496972 DOI: 10.1038/sj.leu.2403560  0.32
2004 Steelman LS, Bertrand FE, McCubrey JA. The complexity of PTEN: mutation, marker and potential target for therapeutic intervention. Expert Opinion On Therapeutic Targets. 8: 537-50. PMID 15584861 DOI: 10.1517/14728222.8.6.537  0.32
2004 Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia. 18: 189-218. PMID 14737178 DOI: 10.1038/sj.leu.2403241  0.32
2003 Larson RA, Daley GQ, Schiffer CA, Porcu P, Pui CH, Marie JP, Steelman LS, Bertrand FE, McCubrey JA. Treatment by design in leukemia, a meeting report, Philadelphia, Pennsylvania, December 2002 Leukemia. 17: 2358-2382. PMID 14562120 DOI: 10.1038/sj.leu.2403156  0.32
2001 Bertrand FE, Vogtenhuber C, Shah N, LeBien TW. Pro-B-cell to pre-B-cell development in B-lineage acute lymphoblastic leukemia expressing the MLL/AF4 fusion protein. Blood. 98: 3398-405. PMID 11719380 DOI: 10.1182/blood.V98.12.3398  0.32
2000 Bertrand FE, Eckfeldt CE, Fink JR, Lysholm AS, Pribyl JA, Shah N, LeBien TW. Microenvironmental influences on human B-cell development. Immunological Reviews. 175: 175-86. PMID 10933602 DOI: 10.1111/J.1600-065X.2000.Imr017513.X  0.32
1998 Bertrand FE, Golub R, Wu GE. V(H) gene replacement occurs in the spleen and bone marrow of non-autoimmune quasi-monoclonal mice European Journal of Immunology. 28: 3362-3370. PMID 9808206 DOI: 10.1002/(SICI)1521-4141(199810)28:10<3362::AID-IMMU3362>3.0.CO;2-8  0.32
1998 Fanning L, Bertrand FE, Steinberg C, Wu GE. Molecular mechanisms involved in receptor editing at the Ig heavy chain locus International Immunology. 10: 241-246. PMID 9533453 DOI: 10.1093/intimm/10.2.241  0.32
1997 Bertrand FE, Billips LG, Burrows PD, Gartland GL, Kubagawa H, Schroeder HW. Ig D(H) gene segment transcription and rearrangement before surface expression of the pan-B-cell marker CD19 in normal human bone marrow Blood. 90: 736-744. PMID 9226174  0.32
1995 Billips LG, Nuñez CA, Bertrand FE, Stankovic AK, Gartland GL, Burrows PD, Cooper MD. Immunoglobulin recombinase gene activity is modulated reciprocally by interleukin 7 and CD19 in B cell progenitors. The Journal of Experimental Medicine. 182: 973-82. PMID 7561700 DOI: 10.1084/Jem.182.4.973  0.32
Show low-probability matches.